Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

250 results about "Tissue specificity" patented technology

Tissue specificity. This subsection of the ‘Expression’ section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms. By default, the information is derived from experiments at the mRNA level, unless specified ‘at protein level’. Examples: P92958, Q8TDN4, O14734.

Improved Methods Controlling Gene Expression

The present invention is in the field of genetics, especially plant genetics, and provides agents capable of controlling gene expression. The present invention specifically provides sequences of naturally occurring, tissue-specifically expressed microRNAs. The invention further provides for transgenic expression constructs comprising sequences encoding said microRNAs. By incorporation of the microRNA encoding sequence the expression from said expression construct is specifically silenced in the tissue where the naturally occurring microRNA is naturally expressed. Thereby the expression profile resulting from the promoter is modulated and leakiness is reduced. The invention further provides for a method for modulating transgenic expression by incorporating sequences encoding said microRNAs into transgenic expression constructs. The compositions and methods of the invention can be used to enhance performance of agricultural relevant crops and for therapy, prophylaxis, research and diagnostics in diseases and disorders, which afflict mammalian species.
Owner:BASF PLANT SCI GMBH

Tissue specific expression of exogenous proteins in transgenic chickens

Transgenes encoding exogenous proteins are stably integrated into embryonic stem cells and are present in the somatic tissue of transgenic or chimeric birds. The transgenes encode exogenous proteins and are expressed in any of endodermal, ectodermal, mesodermal, or extra embryonic tissue. Tissue specificity is provided by selecting the content of the transgene accordingly. Transgenic birds whose genome is comprised of trangene derived exogenous DNA express exogenous proteins with tissue specificity, and specifically express exogenous proteins in the tubular gland cells of the oviduct to concentrate exogenous proteins in egg white..
Owner:SYNAGEVA BIOPHARMA CORP

Primary separation and culture method of human amniotic mesenchymal stem cells

The invention relates to a primary separation and culture method of human amniotic mesenchymal stem cells. The primary separation and culture method of the human amniotic mesenchymal stem cells comprises the following steps of: providing a human amniotic tissue, washing with PBS (phosphate buffer saline), shearing into pieces, adding 0.1-0.3% (by mass) trypsinase to digest, adding I-type collagenase and basal high-glucose DMEM until the final concentration of the I-type collagenase is 0.1-0.2%, digesting, separating the digested human amniotic tissue centrifugally to obtain a precipitate, resuspending the precipitate with PBS, filtering, separating centrifugally, and removing the supernatant to obtain the human amniotic mesenchymal stem cells. Compared with the prior art, the primary separation and culture method provided by the invention has the advantages that because a small amount of trypsinase is used to pretreat and loosen the human amniotic tissue, and further the I-type collagenase with good tissue specificity is used to treat the human amniotic tissue, the digesting time can be shortened greatly, the primary separation steps can be simplified, the human amniotic mesenchymal stem cells can be obtained at a high yield, and the viability of the obtained human amniotic mesenchymal stem cells can be improved greatly compared with that of the human amniotic mesenchymal stem cells in the prior art.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD

HGG (Human Gammaglobulin) polypeptide in combination with tissue specificity of cerebral arterial thrombosis and application thereof

The invention discloses HGG (Human Gammaglobulin) polypeptide in combination with the tissue specificity of cerebral arterial thrombosis. The invention relates to a method for obtaining the polypeptide. The method comprises the following steps: carrying out in-vivo selection of a mouse MCAO (Middle Cerebral Artery Occlusion) cerebral arterial thrombosis model by adopting an in-vivo phage display peptide library screening technology so as to obtain phage clones in combination with cerebral arterial thrombosis tissue; and randomly selecting the plurality of phage clones to sequence, and authenticating the in-vivo combination specificity of HGG peptide and coded phage clones HGG-M13 thereof. The invention further relates to application of the polypeptide in preparation of a high-sensitivity imaging molecular probe and a targeting delivery neuroprotective drug for cerebral stroke. The polypeptide can be synthesized through an artificial method; the polypeptide is low in molecular weight, high in activity and penetrating power, good in specificity and low in toxicity, and has good tissue targeting of cerebral arterial thrombosis in vivo; and therefore, the polypeptide is applicable to serving as a carrier of the high-sensitivity imaging molecular probe and the targeting delivery neuroprotective drug.
Owner:SOUTHEAST UNIV

New cartilaginous affinity polypeptide sequence, screening method and application thereof

The invention discloses a new cartilaginous affinity polypeptide sequence and a screening method thereof. In the invention, according to an improved phage display technique, a cell and tissue layers combined extracorporeal screening method is applied to cartilaginous affinity polypeptide screening for the first time so as to screen out the polypeptide sequence DWRVIIPPRPSA with chondrocyte affinity and tissue specificity, and thus, the drawback of simple cell screening or tissue screening in the prior art is overcome, and the cellular affinity and the tissue specificity are well combined. The invention also relates to the application of the polypeptide in the preparation of a targeted PEI nano-carrier for the gene therapy of mediated articular cartilage diseases, which realize the decoration on the PEI carrier by the cartilaginous affinity polypeptide, offers the cartilaginous tissue specificity and the cellular affinity to the carrier, and realizes the targeted therapy to the cartilage. In addition, the invention takes the chondrocyte itself as the screening target, which has better targeted effect and clinical practical value compared with the mode of taking the matrixes around the chondrocyte as the screening target in the prior art.
Owner:PEKING UNIV THIRD HOSPITAL

Tissue Specific Expression of Exogenous Proteins in Transgenic Chickens

Transgenes encoding exogenous proteins are stably integrated into embryonic stem cells and are present in the somatic tissue of transgenic or chimeric birds. The transgenes encode exogenous proteins and are expressed in any of endodermal, ectodermal, mesodermal, or extra embryonic tissue. Tissue specificity is provided by selecting the content of the transgene accordingly. Transgenic birds whose genome is comprised of trangene derived exogenous DNA express exogenous proteins with tissue specificity, and specifically express exogenous proteins in the tubular gland cells of the oviduct to concentrate exogenous proteins in egg white.
Owner:SYNAGEVA BIOPHARMA CORP

Tissue-specific gene and regulatory factor data storage method

The invention discloses a tissue-specific gene and regulatory factor data storage method. In the method, data storage is realized by establishing a tissue-specific gene and regulatory factor database comprising a tissue bank, a gene bank, a gene reference name bank, a tissue-specific gene bank and the tissue bank of tissue-specific genes. The method comprises the following steps of: extracting the tissue-specific genes from a Pubmed bibliographic database in a literature mining form; adding extracted tissue information into the tissue bank; retrieving information about the genes in the European Molecular Biology Laboratory (EMBL), Genebank and NCBI by utilizing names of the genes, and adding the information into corresponding items of the gene bank; and generating regulatory factor XML files by utilizing the information of regulating the searching of the genes from Transfac, an Eukaryotic Promoter Database (EPD) and a compel database. Compared with the prior art, the method has the advantages of bringing convenience to researchers utilizing modern computing technology to detect gene expression and regulate an inherent mechanism of network tissue specificity to acquire data on sequences of the tissue-specific genes and corresponding regulatory factors, fully utilizing tissue-specific gene analysis tools and improving research quality and efficiency.
Owner:TIANJIN UNIV

Method for conditional knockout of Lox13 gene of mouse and application

The invention relates to a method for conditional knockout of Lox13 gene of a mouse and an application. The method comprises the steps that loxP loca of a Cre recombinase targeting sequence are added to the two ends of a key exon of an Lox13 gene; a conditional gene knockout carrier is constructed, and transfected with an embryonic stem cell (ESC); microinjection is conducted for making a floxed mouse capable of being used for conditional gene knockout; the floxed mouse is mated with a Cre mouse with corresponding tissue specificity; and the mouse of which an Lox13 gene can be knocked out at a specific tissue is obtained. The mouse obtained by the method serves as a model mouse for morbidity research on a cleft palate disease, so that the functions of the Lox13 gene in the tissue and the effects of the Lox13 gene in an embryonic development regulation mechanism can be illustrated in details. In addition, the mouse can serve as an animal model for researching the functions of the Lox13 gene, and has important application values.
Owner:SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products